The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007)

Lemp, Michael A.; Baudouin, Christophe; Baum, Jules; Doğru, Murat; Foulks, Gary N.; Kinoshita, Shigeru; Laibson, Peter R.; McCulley, James P.; Murube, Juan; Pflugfelder, Stephen C.; Rolando, Maurizio; Toda, Ikuko

doi:10.1016/s1542-0124(12)70081-2

Cited by 2,620 publications

(390 citation statements)

References 203 publications

Supporting

Mentioning

378

Contrasting

Unclassified

Order By: Relevance

“…Optimal and consistent clinical results are directly related to the preparation and composition of these products [8], as well as the assurance of their biological stability after preparation. The poor standardization of preparation protocols, and consequently of blood-based eyedrops, including AS has resulted in inconclusive and controversial results [15]. …”

Section: Discussionmentioning

confidence: 99%

Autologous Plasma Rich in Growth Factors Eyedrops in Refractory Cases of Ocular Surface Disorders

et al. 2015

View full text Add to dashboard Cite

Purpose: Preliminary information about the safety and efficacy of plasma rich in growth factors (PRGF) eyedrops in the treatment of refractory cases of diverse ocular surface disorders (OSDs) is presented here. Material and Methods: This retrospective cohort study included cases with OSDs refractory to previous treatment with conventional treatments or autologous serum or cyclosporine, and treated with PRGF eyedrops. The signs and symptoms of ocular surface disorders [using the ocular surface disease index (OSDI), best-corrected visual acuity (BCVA), visual analog scale (VAS) frequency and VAS severity] were evaluated before and after treatment with PRGF. A safety assessment was also performed reporting all adverse events or complications. Results: Forty-one patients with a total of 80 treated eyes were evaluated. Statistically significant reductions in the OSDI scale (39.27%), VAS frequency (38.9%) and VAS severity (40.3%), and a significant improvement in BCVA (54.86%) were all observed (p < 0.05). The results were stratified according to the identified potential effect modifiers. There were only two adverse events (eye redness and eyelid inflammation), which were reported as mild and resolved in a few days. Conclusions: PRGF eyedrops could be a safe and effective treatment option for refractory cases of OSDs. When treating patients the possible influence on the results of some clinical variables must be taken into account.

show abstract

Section: Discussionmentioning

confidence: 99%

Autologous Plasma Rich in Growth Factors Eyedrops in Refractory Cases of Ocular Surface Disorders

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Dry eye disease (DED) is one of the most common diseases in ophthalmology and is estimated to affect between 5 and 30% of the population with very high socioeconomic costs and a high impact on patients' quality of life [1,2]. It is well known that the incidence of the disease increases with age and has a higher prevalence in women than men [3,4].…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry Eye

Merayo‐Lloves

Sánchez-Ávila²,

Riestra³

et al. 2016

Ophthalmic Res

View full text Add to dashboard Cite

Purpose: To provide preliminary information about the safety and efficacy of plasma rich in growth factors (PRGF) in the treatment of evaporative dry eye (EDE) and analyze the influence of certain variables on treatment outcomes. Methods: This retrospective study included patients with EDE treated between January 2011 and December 2013. Outcome measures including signs and symptoms of the disease were evaluated before and after treatment. The influence of some of the patient's clinical variables on results was assessed. Safety assessment was also performed. Results: Eighty-three patients with a total of 156 eyes were evaluated. Statistically significant reductions in the Ocular Surface Disease Index (38.2%), best-corrected visual acuity (27.4%), Visual Analogue Scale scores for frequency (32%) and severity (34%), and a significant improvement in the Schirmer test scores (177.5%) were observed (p < 0.05). The results were stratified according to the identified potential effect modifiers. Only four adverse events were reported. All of them were mild and resolved within a few days. Conclusions: Results suggest that PRGF eye drops could be a safe and effective treatment in reducing EDE signs and symptoms. When treating patients, the possible influence of some clinical variables must be taken into account.

show abstract

“…An increase in tear osmolarity is a hallmark of dry eye disease and is thought to be the central mechanism in the pathogenesis of ocular surface damage in the disease, as noted in the Dry Eye Workshop Report. Tear osmolarity has been reported to be the single best marker for dry eye disease [11]. …”

Section: Introductionmentioning

confidence: 99%

Tear Film Osmolarity in Patients with Diabetes Mellitus

et al. 2013

View full text Add to dashboard Cite

Purpose: To compare tear film osmolarity (TFO) between patients with diabetes mellitus (DM) and normal healthy individuals. Methods: In this prospective case-controlled study, the TFO in 46 normal subjects (control group) and 55 patients with DM (study group) was evaluated. TFO in milliosmole (mOsm) was measured by using an auto-osmometer. The serum levels of glycosylated hemoglobin (HbA₁c) and blood glucose in all participants were also measured. Mean outcome measures were TFO and its relationship with HbA1c level and duration of DM. Results: Mean TFO was 320.40 ± 21.80 mOsm/l in the study group and 308.22 ± 18.16 mOsm/l in the control group (p < 0.001). The TFO values were significantly associated with duration of DM (r = 0.476, p < 0.001), but no significant correlation was found with HbA₁c level (r = 0.225, p = 0.114). Conclusions: The study shows a significantly higher TFO in patients with DM than in the healthy controls. TFO also correlates with the duration of DM.

show abstract

The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007)

Cited by 2,620 publications

References 203 publications

Autologous Plasma Rich in Growth Factors Eyedrops in Refractory Cases of Ocular Surface Disorders

Autologous Plasma Rich in Growth Factors Eyedrops in Refractory Cases of Ocular Surface Disorders

Safety and Efficacy of Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry Eye

Tear Film Osmolarity in Patients with Diabetes Mellitus

Contact Info

Product

Resources

About